Literature DB >> 23174066

Clinical outcomes of zone II flexor tendon repair depending on mechanism of injury.

Trevor Starnes1, Rebecca J Saunders, Kenneth R Means.   

Abstract

PURPOSE: To determine whether mechanism of injury affects outcomes of Zone II flexor tendon repairs.
METHODS: We retrospectively analyzed patients who underwent Zone II flexor tendon repair between 2001 and 2010 with a minimum of 12-month follow-up. Exclusion criteria included fingers with fracture, pulley reconstruction, or flexor tendon bowstringing. The saw group injuries were from saws or from tearing mechanisms; the sharp group had clean transection injuries from knives or glass. At final evaluation, primary outcomes were total passive motion (TPM) and total active motion (TAM) at the proximal interphalangeal and distal interphalangeal joints. Secondary comparisons included strength, Disabilities of the Shoulder, Arm, and Hand (DASH) score, percentage of postoperative tendon rupture, and percentage of patients requiring secondary surgery. The saw group had 13 patients with 17 fingers studied. The sharp group had 21 patients with 24 fingers studied. All patients had primary flexor digitorum profundus repairs in Zone II. Operative records review confirmed for all but 1 patient that flexor digitorum profundus injuries were repaired with a minimum of a 4-strand core suture technique. In the saw group, 9 of 14 fingers with a 50% or greater laceration of flexor digitorum superficialis were repaired; in the sharp group, 15 of 18 such flexor digitorum superficialis injuries were repaired. Average follow-up was 4 years (range, 1-9 y).
RESULTS: The saw group had significantly less TAM and TPM compared with the sharp group. There was no significant difference in DASH scores, strength measurements, or tendon rupture rates. The rate of secondary surgery was significantly higher in the saw group.
CONCLUSIONS: Tearing types of injury, such as those caused by saws, led to poorer outcomes for Zone II flexor tendon injuries compared with sharp injuries at an average follow-up of 4 years. Our results can be useful when discussing expected outcomes. Mechanism of injury in Zone II flexor tendon lacerations may eventually help define optimal treatment.
Copyright © 2012 American Society for Surgery of the Hand. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23174066     DOI: 10.1016/j.jhsa.2012.09.021

Source DB:  PubMed          Journal:  J Hand Surg Am        ISSN: 0363-5023            Impact factor:   2.230


  6 in total

Review 1.  [Rehabilitation after flexor tendon injuries of the hand].

Authors:  A Asmus; S Kim; M Millrose; J Jodkowski; A Ekkernkamp; A Eisenschenk
Journal:  Orthopade       Date:  2015-10       Impact factor: 1.087

2.  Zone II Flexor Pollicis Longus Repair: Thumb Flexion and Complications.

Authors:  Luca L Bruin; Jonathan Lans; Kyle R Eberlin; Neal C Chen
Journal:  Hand (N Y)       Date:  2020-07-01

3.  Effect of Time to Hand Therapy following Zone II Flexor Tendon Repair.

Authors:  Shepard P Johnson; Brian P Kelley; Jennifer F Waljee; Kevin C Chung
Journal:  Plast Reconstr Surg Glob Open       Date:  2020-12-21

4.  Beyond the Core Suture: A New Approach to Tendon Repair.

Authors:  Weifeng Zeng; Nicholas J Albano; Ruston J Sanchez; Ronald Mccabe; Ray Vanderby; Samuel O Poore; Aaron M Dingle
Journal:  Plast Reconstr Surg Glob Open       Date:  2020-12-17

5.  Functional outcomes after flexor tendon repair of the hand.

Authors:  Taryn Spark; Lonwabo Godlwana; Veronica Ntsiea; Eileen Du Plooy; Charl Janse van Rensburg
Journal:  Turk J Phys Med Rehabil       Date:  2019-11-22

6.  Functional and Disability Assessment Among Hispanics With Zone 2 Flexor Tendon Injuries: Comparative Study Between Flexor Digitorum Superficialis Repair and Flexor Digitorum Superficialis Excision.

Authors:  Eduardo J Natal-Albelo; Gerardo Olivella; Giovanni U Paraliticci-Márquez; Lenny Rivera; Gabriel Echegaray; Norman Ramírez; Christian A Foy-Parrilla
Journal:  J Am Acad Orthop Surg Glob Res Rev       Date:  2020-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.